相关实验视频
Updated: Jun 8, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
GLP-1受体激动剂对体重和心血管结果的影响:一篇综述
Fatima Ali Raza1, Rafiya Altaf2, Talha Bashir3
1Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
Medicine
|November 4, 2024
概括
葡萄糖类1受体激动剂 (GLP-1 RAs) 为肥胖症治疗提供了一个有前途的药理学方法,有助于显著减肥,并可能改善心血管健康. 本综述详细介绍了它们的机制,好处和管理策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 肥胖症的治疗通常需要药理干预,因为饮食和生活方式的限制改变长期减肥.
- 越来越多的人需要有效的药物来控制肥胖及其相关的危及生命的疾病.
- 葡萄糖样1受体激动剂 (GLP-1RA) 已成为肥胖药物治疗的一个关键领域.
研究的目的:
- 在体重管理的背景下,审查GLP-1RA的作用机制.
- 探索GLP-1RA对减肥的疗效及其对心血管风险因素和结果的影响.
- 讨论GLP-1RAs的不良影响及其管理策略.
主要方法:
- 这篇叙述性综述综合了关于用于治疗肥胖的GLP-1RA的当前研究.
- 文献搜索的重点是研究GLP-1RA机制,减肥效应,心血管益处和安全概况的研究.
- 该审查包括了FDA批准的GLP-1RA (如西马格卢提德和利拉格卢提德) 的信息.
主要成果:
- GLP-1 RAs促进显著和持续的减肥,解决传统肥胖治疗的关键局限性.
- 这些药物已经在肥胖患者中显示出有前途的心血管益处的早期证据.
- 最初用于2型糖尿病的塞马格卢提德和利拉格卢提德现在已被批准用于减肥,因为它们已证明有效.
结论:
- GLP-1 RAs代表了药理肥胖治疗的重大进步,提供了大量的减肥.
- 它们的潜在心血管益处增加了它们在治疗肥胖患者中的临床价值.
- 了解GLP-1RA的机制,疗效和不良影响对于有效的临床应用至关重要.
相关概念视频
Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
160
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
160
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
GPCRs Regulate Adenylyl Cylase Activity
5.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K

